Aspen Pharmacare Australia Pty Ltd (Aspen) is pleased to announce a new partnership with Eli Lilly Australia (Lilly) for ZyprexaÂ® (olanzapine), a market leading medication for schizophrenia and bipolar disorder
Under the alliance Aspen will support the marketing and promotion of Zyprexa®. Aspen will commence promoting Zyprexa® in January, and will also be responsible for selling the Lilly generic brand Lanzek® (olanzapine).
Aspen has a long-standing relationship with Lilly, having partnered with the company on Evista® (raloxifene hydrochloride) and is pleased to be continuing this relationship; especially on Zyprexa® which has been and will continue to be an extremely important medication for Australian patients.
Content Last Reviewed On July 16, 2018